HK1237000B - 用於鉴别患者以使用醋酸阿比特龙治疗的生物标志物 - Google Patents

用於鉴别患者以使用醋酸阿比特龙治疗的生物标志物 Download PDF

Info

Publication number
HK1237000B
HK1237000B HK17109647.9A HK17109647A HK1237000B HK 1237000 B HK1237000 B HK 1237000B HK 17109647 A HK17109647 A HK 17109647A HK 1237000 B HK1237000 B HK 1237000B
Authority
HK
Hong Kong
Prior art keywords
patient
expression level
abiraterone acetate
mrna biomarker
expression
Prior art date
Application number
HK17109647.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1237000A1 (zh
Inventor
Sokol Ricci Deborah
Li Weimin
Gormley Michael
Karkera Jayaprakash
Schaffer Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1237000A1 publication Critical patent/HK1237000A1/zh
Publication of HK1237000B publication Critical patent/HK1237000B/zh

Links

HK17109647.9A 2014-05-12 2015-05-07 用於鉴别患者以使用醋酸阿比特龙治疗的生物标志物 HK1237000B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61/991,710 2014-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK42021038618.1A Division HK40048782B (zh) 2014-05-12 2017-09-22 用於监定患者以使用醋酸阿比特龙进行治疗的生物标志物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42021038618.1A Addition HK40048782B (zh) 2014-05-12 2017-09-22 用於监定患者以使用醋酸阿比特龙进行治疗的生物标志物

Publications (2)

Publication Number Publication Date
HK1237000A1 HK1237000A1 (zh) 2018-04-06
HK1237000B true HK1237000B (zh) 2021-12-17

Family

ID=

Similar Documents

Publication Publication Date Title
JP2022031750A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
Guo et al. Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer
EP3299478A1 (en) Methods for predicting drug responsiveness in cancer patients
Muñoz-Rodríguez et al. Differentially expressed microRNAs in postpartum breast cancer in Hispanic women
US20200129482A1 (en) Treatment of non-small cell lung cancer
JP7093802B2 (ja) 酢酸アビラテロン治療の対象となる患者を同定するための生物学的マーカー
Boerrigter et al. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line Abiraterone acetate and prednisone treatment
US20180092930A1 (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
EP2092087B1 (de) Prognostische marker für die klassifizierung von kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
EP3676404B1 (en) Methods of selecting a treatment for breast cancer patients
EP3464623B1 (en) Androgen receptor splice variants and androgen deprivation therapy
HK40048782B (zh) 用於监定患者以使用醋酸阿比特龙进行治疗的生物标志物
HK40048782A (zh) 用於监定患者以使用醋酸阿比特龙进行治疗的生物标志物
HK1237000A1 (zh) 用於鉴别患者以使用醋酸阿比特龙治疗的生物标志物
HK1237000B (zh) 用於鉴别患者以使用醋酸阿比特龙治疗的生物标志物
Brenner et al. Analyses of synovial tissues from arthritic and protected congenic rat strains reveal a new core set of genes associated with disease severity
EP3535421B9 (en) Diagnostic methods
EP3551761B1 (en) Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy
Khalid et al. Clinical impact of somatic genomic testing on breast cancer care
EP4660323A1 (en) Prognosis prediction method for metastatic hormone-sensitive prostate cancer
Hiew The Prognostic Potential of the Long Non-Coding RNA MALAT1 and LDH Related Metabolism in Prostate Cancer
CN118043473A (zh) 用于治疗肾脏同种异体移植物纤维化和排斥反应以及诊断其风险的方法
Chan et al. O-49 A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer